In breast cancer, robust IFN-γ gene signatures have been linked to favorable survival and higher pathological complete response rates to neoadjuvant therapy, particularly in immune-rich HER2+ and TNBC subtypes [14]. The gene discussed is IFNG; the disease is breast carcinoma.